Advice

Following an abbreviated submission.

Seretide 50 Evohaler is accepted for use within NHSScotland for the regular treatment of asthma where use of a combination of the long-acting beta agonist salmeterol and the inhaled corticosteroid fluticasone is appropriate for a child aged 4-12 years.

The acquisition cost of the combination product is less than for the individual components given by aerosol inhalation and for the combination given by Accuhaler?.

Download detailed advice25KB (PDF)

Download

Medicine details

Medicine name:
Seretide 50 Evohaler (Salmeterol xinafoate 25mcg/fluticasone propionate 50mcg)
SMC ID:
108/04
Indication:
Asthma
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Respiratory system
Submission type
Abbreviated
Status
Accepted
Date advice published
12 July 2004